Dr. Michael Leapman presented “Can Genomics Improve Upon Best Clinical Risk Stratification?” at the 22nd Annual Scottsdale Prostate Cancer Symposium on Thursday, March 16, 2017.



How to cite: Leapman, Michael  “Can Genomics Improve Upon Best Clinical Risk Stratification?” March 16, 2017. Accessed Jul 2024. https://grandroundsinurology.com/can-genomics-improve-upon-best-clinical-risk-stratification



Dr. Leapman is an Assistant Professor of Urology at the Yale School of Medicine in New Haven, Connecticut. He was drawn to the field of urology by the opportunity to care for patients with urologic cancers. Dr. Leapman graduated from Cornell University, where he majored in Neurobiology and Behavior, and received his medical degree from the University of Maryland in Baltimore. He completed his General Surgery and Urology training at the Mount Sinai Hospital in New York City. Subsequently, he completed a two-year Urologic Oncology Fellowship at the University of California, San Francisco (UCSF), accredited by the Society of Urologic Oncology. He was recruited to join the faculty at the Yale University School of Medicine Smilow Cancer Center in 2016. He specializes in urologic oncology, and has a joint appointment at the West Haven Veterans Affairs Medical Center. His clinical interests include low-risk prostate cancer, active surveillance, nerve-sparing robotic prostatectomy, focal therapy, high-risk disease, and pelvic lymph node dissection.